Australian MPs visit Southport GP to learn about low carb diet for type 2 diabetes

Source: BMJ News - Category: General Medicine Source Type: research

Related Links:

ConclusionsHuman IGF-1 gene may be a candidate gene for GDM and T2DM risk, as our study suggests a significant association between the IGF-I rs35767 and rs5742612 polymorphisms and the risk of T2DM and GDM in pregnant women, whereas there was no association for rs2288377.
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
Conclusions: Laparoscopic sleeve gastrectomy is a safe and effective procedure, with good results in the short and medium term. Long-term follow-up reveals a tendency to weight regain after approximately 2 years from primary surgery, with the need for revisional surgery in some cases. PMID: 31118990 [PubMed]
Source: Videosurgery and Other Miniinvasive Techniques - Category: Surgery Tags: Wideochir Inne Tech Maloinwazyjne Source Type: research
ConclusionsMGD in type 2 diabetic patients is more severe compared with nondiabetic patients. Longer duration of diabetes is associated with major symptoms and changes in MG. Diabetic group showed major changes in lids and tear function, accounting for evaporative dry eye and presenting a high degree of correlation with MG inflammation and obstruction.ResumenObjetivoEvaluar las glándulas de Meibomio, la superficie ocular y la función de la lágrima en pacientes con diabetes tipo 2, y estudiar la correlación entre estas situaciones.MétodosEstudio prospectivo de 76 varones, 37 de ellos con d...
Source: Journal of Optometry - Category: Opthalmology Source Type: research
I chose endocrinology to be my lifelong profession out of love for the complex interactions of endocrine glands and intricate feedback loops. I take pride in preventing medical complications, prolonging life expectancy, and providing complex care to type 1 and type 2 diabetics. At times, this field of work requires spending hours— either with […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Physician Diabetes Endocrinology Source Type: blogs
ConclusionsOur results identify a novel ERK/hnRNPK/DDX3X pathway that influences β cell survival and is activated under conditions associated with T2D.
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
DiabetesMine interviews T'ara Smith, head of the new Beyond Type 2 platform, on getting the right diabetes diagnosis and finding a support community.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs
Conclusion MethodologyThere were 4 clinical trials approved at the National University Malaysia in collaboration with Cytopeutics (Cyberjaya, Malaysia) which provided the mesenchymal stromal cells (Cyto-MSC) for treatment of acute stroke, heart failure, diabetes with critical limb ischemia and severe deforming osteoarthritis. All patients received 65-130 × 106 Cyto-MSC intravenously. Severity of chronic kidney disease is based on baseline estimated glomerular filtration rate (eGFR) and serum creatinine which are markers of renal dysfunction. These and other blood tests including fasting blood sugar (FBS) and Hba1...
Source: Cytotherapy - Category: Cytology Source Type: research
FRIDAY, May 24, 2019 -- Type 2 diabetes mellitus (T2DM) is a risk factor for progression of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), according to a study published online May 21 in the Journal of Gastroenterology and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ARTEMIS findings suggest efforts should be made to prevent progression to type 2 diabetes for patients with treated coronary artery disease and prediabetes.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
There ’s been an odd-sounding word circulating in the English headlines recently.The word is Orkambi; a drug created by Vertex that treats approximately 40% of people born with the genetic condition, cystic fibrosis. It is the second drug to market in a promising pipeline that targets the CFTR mutation.   True gene therapy it isn’t, but it represents a near-first for a biotech firm, by successfully altering the shape and function of a protein[1]. And priced at £105,000 per patient per year, it is the latest in a long line of medicines the NHS can’t afford.Orkambi has been licensed by the EMAsin...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
More News: Australia Health | Diabetes | Diabetes Type 2 | Diets | Endocrinology | General Medicine | Learning | Nutrition | Universities & Medical Training